
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is in a strong position with a diverse pipeline, a track record of successful partnerships, and a focus on unmet medical needs. Their financials show positive growth with solid revenues and a net income of $83.8 million in the first quarter of 2021. Additionally, the company's strategic partnerships and collaborations provide access to resources and expertise that can support the development and commercialization of their products. These factors, combined with the potential for their orexin portfolio and other products, make Alkermes a favorable investment opportunity with strong potential for growth in the biotechnology industry.
Bears say
Alkermes is positioned well for long-term growth in the biotechnology sector with its proprietary technologies and established partnerships. However, the limited efficacy of their orexin drugs in addressing the core symptoms of IH and ADHD, and competition from other approved treatments may limit its potential. Additionally, the small sample sizes in studies may not fully support the efficacy of their drugs, and their position as a second-to-market may pose challenges in gaining market share.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares